This brief summarizes key findings from a literature review conducted by PATH to identify published and gray literature reporting international experiences with the Uniject™ injection system. The findings shed light on user acceptability and highlight potential cost savings in terms of training time, waste management, and reduction in drug wastage when Uniject is used instead of a standard autodisable syringe. This document synthesizes the experience and evidence on the use of Uniject worldwide with medicines such as the injectable contraceptive Cyclofem®, hepatitis B and tetanus toxoid vaccines, as well as the drug oxytocin, which is used to prevent postpartum hemorrhage.
Corporate author(s): PATH
Publication date: February 2011
715 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA